International law firm McDermott Will & Emery represented Scipher Medicine, a precision immunology company matching patients with the most effective therapy, in the completion of its Series C financing. aMoon, an investment fund based in Israel, and Northpond Ventures, a US-based VC fund, led the funding with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures. To date, the company has raised $117 million.
Scipher Medicine will use the proceeds to expand commercial efforts for its patient molecular signature test, PrismRA®, ensuring rheumatoid arthritis patients are prescribed optimal targeted therapy from day one, and data collaborations to discover novel treatment targets based on their large and growing patient clinico-genomic database generated from tested patients. “With more data being generated from tested patients every day, we are continuously serving our provider, payer, and pharma partnerships with unique insights into the most optimal treatment pathway for patients with autoimmune diseases,” Alif Saleh, Chief Executive Officer at Scipher, said.
“We are proud to represent Scipher on this seminal transaction, the most recent since partnering with them under LEAP, our Life Science Entrepreneur Acceleration Program,” Byron Kalogerou, lead relationship partner, said. “We are truly honored to support Scipher’s remarkable trajectory and its mission.”
Brian Bunn and Jacob Kuipers led the McDermott deal team.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Kerri Chace+1 617 535 4145